Zai Lab (ZLAB) Debt Ratio (2018 - 2026)

Zai Lab (ZLAB) reported Debt Ratio of 0.2 for Q1 2026, up 32.04% on a YoY basis from 0.15 in Q1 2025, and up 11.85% sequentially from 0.17 in Q4 2025.

Zai Lab (ZLAB) Debt Ratio (2018 - 2026) Analysis & Trends

Zai Lab (ZLAB) has 5 years of Debt Ratio data on file, last reported at 0.2 in Q1 2026.

  • For the quarter ending Q1 2026, Debt Ratio rose 32.04% year-over-year to 0.2; the trailing twelve-month figure through Mar 2026 stood at 0.2 (up 32.04% YoY), and the FY2025 full-year result was 0.17, up 57.06% from the prior year.
  • Debt Ratio improved to 0.2 in Q1 2026, from 0.17 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.2 in Q1 2026 to a low of 0.05 in Q1 2024.
  • A 3-year average of 0.13 and a median of 0.15 in 2025 frame the typical range for Debt Ratio.
  • Across the five-year window, Debt Ratio soared 202.61% in 2025 and jumped 32.04% in 2026, its largest moves.
  • Tracing ZLAB's Debt Ratio over 3 years: stood at 0.11 in 2024, then soared by 57.06% to 0.17 in 2025, then rose by 11.85% to 0.2 in 2026.
  • Business Quant data shows ZLAB's Debt Ratio at 0.2 in Q1 2026, 0.17 in Q4 2025, and 0.18 in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Debt Ratio (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - 1.41
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 0.11
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn -
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 0.05
7 Belite Bio 61.40 Bn 61.40 Bn - -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn -
9 Revolution Medicines 37.37 Bn 37.37 Bn - -
10 Zai Lab 21.37 Bn 21.37 Bn -34.26 Mn 0.20

Historic Data

Download Data
DateValue
Mar 31, 2026 0.20
Dec 31, 2025 0.17
Sep 30, 2025 0.18
Jun 30, 2025 0.15
Mar 31, 2025 0.15
Dec 31, 2024 0.11
Sep 30, 2024 0.11
Jun 30, 2024 0.07
Mar 31, 2024 0.05
Dec 31, 2019 0.02
Dec 31, 2018 0.01